# A Long-term Efficacy and Safety of NTQ5082 Capsules

> **NCT07177872** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 78 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** NTQ5082 capsules 200 mg

## Key facts

- **NCT ID:** NCT07177872
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177872, "A Long-term Efficacy and Safety of NTQ5082 Capsules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07177872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*